(Q51907858)

English

Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.

scientific article published in January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mattia Prosperi

5

object named as

Mattia Prosperi

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

Simona Di Giambenedetto

1

object named as

Simona Di Giambenedetto

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

Carmela Pinnetti

1 reference

ORCID Public Data File 2021

author name string

Alessanra Bacarelli

2

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Carmen Pinnetti

3

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Manuela Colafigli

4

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Giorgio Gatti

6

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Roberto Cauda

7

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Andrea De Luca

8

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

39

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

9

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

813-818

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance

1 reference

https://api.crossref.org/works/10.1080%2F00365540701367728

21 January 2018

Identifiers

10.1080/00365540701367728

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17701721

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51907858&oldid=1580718871"